This review discusses recent developments in the field of nanosized biomaterials and their use in tissue regeneration approaches. The aim is to provide an overview of the research focused on nanoparticle-based strategies to stimulate regeneration. In particular, nanoparticles improve the Regenerative capabilities of biomaterials offering ways to control surface and mechanical properties. Moreover, incorporation of nanoparticles within biomaterials increases cellular adhesion, differentiation and integration of stem cells into the surrounding environment. Finally, the drug delivery capabilities of nanoparticles offer additional possibilities to increase the biological performance of biomaterials. As the development of nanoparticles continues, incorporation of this technology in the field of Regenerative medicine will ultimately lead to new tools that can diagnose, track and stimulate the growth of new tissues and organs.

Regenerative medicine is a novel interdisciplinary discipline in medicine dealing with the production of new or re-engineered tissues (either functional or living) to use the product instead of a tissue or an organ (1),the source of this new tissue or organ could be human or animal cells, tissues or organs, and the goal are to restore the function of the tissue or the organ (2). . . .

Dear Editor, Regenerative medicine is a developing field of medicine that has been used in both labs and clinics with the main aim of healing damaged parts through repairing, replacing, and regenerating the cell of the body (1, 2). Regenerative medicine, including soluble molecules (proteins, cytokines, growth factors), biomaterials (biomaterials are natural or synthetic substances used for the creation of skin substitutes in clinical applications), tissue engineering (in dermatology, numerous studies in the field of tissue engineering have been translated already into therapeutical applications, like for the treatment of chronic wounds), gene therapy (gene therapy approach is perfectly eligible for the treatment of diseases involving recessive loss-of-function mutations, as it occurs in junctional or recessive dystrophic epidermolysis bullosa (EB)), cell therapy (bone marrow and adipose mesenchymal stem cells present further suitable candidates for cell therapy) and cell reprogramming (induced pluripotent stem cells (iPS) were phenotypically and functionally indistinguishable from embryonic stem cells)...